The prior authorization process in American healthcare has functioned like a toll booth operated by someone who hates cars. Before a specialty drug reaches a patient, a physician must submit a request, a payer reviews it against criteria, a reviewer may ask for more documentation, the practice follows up, and eventually, days or weeks later, a decision arrives.
Forus Health built the AI infrastructure to collapse that timeline from weeks to hours. On September 13, 2026, the company announced a $150 million Series C funding round at a $3 billion valuation. Five of the top ten biopharma companies in the world are paying customers. The round was led by existing investors and marks the third major funding event for a company that did not exist three years ago.
This is not a story about automation for its own sake. It is a story about where the money flows in healthcare and why a company that sits at the intersection of biopharma revenue cycles and clinical workflow just became a $3 billion …
